Glaxo U.S. Pharma Head Says 'Unfettered Pricing' Days Are Gone
- Focused on making operations 'faster, better, cheaper:' Bailey
- Glaxo could consider split, but still a few years off
This article is for subscribers only.
As drugmakers face rising criticism for boosting prices, GlaxoSmithKline Plc’s U.S. pharmaceuticals president Jack Bailey is working on bringing new drugs to market as efficiently as possible.
“The days of unfettered pricing are long gone,” Bailey said in an interview at Bloomberg’s headquarters in New York. “There is still price being taken, but in all likelihood it’s going to continue to come under deep, deep scrutiny.”